Blueprint Medicines (BPMC) PT Lowered to $65 at Morgan Stanley on Reduced Avapritinib PoS
Tweet Send to a Friend
Morgan Stanley analyst Michael Ulz lowered the price target on Blueprint Medicines (NASDAQ: BPMC) to $65.00 (from $92.00) ahead of ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
